BACKGROUND & AIMS: VP22-mediated intercellular transport provides an approach to deliver functional chimeric proteins into a high percentage of target cells. The aim of this study was to evaluate the efficacy of p53/VP22 fusion protein in gene therapy of liver tumors. METHODS: Expression vectors of N- and C-terminal fusion proteins of p53 and VP22 were subcloned and transcriptional properties of chimeric proteins were assessed by luciferase assays. Adenoviral vectors expressing p53 wild type (AdGFP/p53wt) and p53-VP22 (AdGFP/p53-VP22) were generated to investigate the VP22-mediated spreading in normal liver and in liver tumors in vivo by green fluorescent protein fluorescence and p53 immunohistochemistry. Gene therapy was investigated in subcutaneous and preclinical orthotopic animal tumor models after subcutaneous and intra-arterial administration of the adenoviruses, and tumor growth was assessed by direct calibration and magnetic resonance imaging. RESULTS: p53-VP22 showed enhanced transcriptional activity compared with p53 wild type. VP22-mediated intercellular transport of p53 could be observed in the normal liver and in liver tumors in vivo and was correlated with increased antitumor efficacy of gene therapy and improved survival of the animals. CONCLUSIONS: Fusion of VP22 to p53 strongly improves the results of p53 replacement gene therapy. Furthermore, the demonstrated VP22-mediated intercellular transport in the liver could be important for other strategies in liver gene therapy, providing a tool for enhancing the effect of gene therapy in liver diseases such as metabolic disorders or viral hepatitis.
BACKGROUND & AIMS: VP22-mediated intercellular transport provides an approach to deliver functional chimeric proteins into a high percentage of target cells. The aim of this study was to evaluate the efficacy of p53/VP22 fusion protein in gene therapy of liver tumors. METHODS:Expression vectors of N- and C-terminal fusion proteins of p53 and VP22 were subcloned and transcriptional properties of chimeric proteins were assessed by luciferase assays. Adenoviral vectors expressing p53 wild type (AdGFP/p53wt) and p53-VP22 (AdGFP/p53-VP22) were generated to investigate the VP22-mediated spreading in normal liver and in liver tumors in vivo by green fluorescent protein fluorescence and p53 immunohistochemistry. Gene therapy was investigated in subcutaneous and preclinical orthotopic animal tumor models after subcutaneous and intra-arterial administration of the adenoviruses, and tumor growth was assessed by direct calibration and magnetic resonance imaging. RESULTS: p53-VP22 showed enhanced transcriptional activity compared with p53 wild type. VP22-mediated intercellular transport of p53 could be observed in the normal liver and in liver tumors in vivo and was correlated with increased antitumor efficacy of gene therapy and improved survival of the animals. CONCLUSIONS: Fusion of VP22 to p53 strongly improves the results of p53 replacement gene therapy. Furthermore, the demonstrated VP22-mediated intercellular transport in the liver could be important for other strategies in liver gene therapy, providing a tool for enhancing the effect of gene therapy in liver diseases such as metabolic disorders or viral hepatitis.
Authors: Saskia A Rutjes; Piter J Bosma; Jennifer L Rohn; Mathieu H M Noteborn; John G Wesseling Journal: J Mol Med (Berl) Date: 2003-07-16 Impact factor: 4.599
Authors: Young Il Kim; Byeong-Cheol Ahn; John A Ronald; Regina Katzenberg; Abhinav Singh; Ramasamy Paulmurugan; Sunetra Ray; Sanjiv S Gambhir; Lawrence V Hofmann Journal: J Vasc Interv Radiol Date: 2012-03-02 Impact factor: 3.464
Authors: Florian Kühnel; Bernd Schulte; Thomas Wirth; Norman Woller; Sonja Schäfers; Lars Zender; Michael Manns; Stefan Kubicka Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: Julia Freimuth; Nikolaus Gassler; Nives Moro; Rolf W Günther; Christian Trautwein; Christian Liedtke; Gabriele A Krombach Journal: Mol Cancer Date: 2010-04-29 Impact factor: 27.401
Authors: Stuart D Perkins; Helen C Flick-Smith; Helen S Garmory; Angela E Essex-Lopresti; Freda K Stevenson; Robert J Phillpotts Journal: Genet Vaccines Ther Date: 2005-04-20